Quanterix Corp. (QTRX), a company focused on digitizing biomarker analysis, said on Friday that it has inked a deal to buy Akoya Biosciences, Inc. (AKYA), a spatial biology company, in an all stock transaction.
Under the terms, Akoya shareholders will receive 0.318 shares of Quanterix for each share of Akoya share owned. This represents a 19 percent premium to Akoya's unaffected stock price on November 14, 2024.
The transaction, to close in the second quarter, will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.
Masoud Toloue, CEO of Quanterix, said: "This transaction accelerates our progress by creating the first platform that lets researchers and clinicians track disease progression from tissue to blood."
Post transaction, Quanterix will own around 70 percent of the combined company, while Akoya will own approximately 30 percent.
The transaction is expected to generate around $40 million in annual cost synergies by the end of 2026, with $20 million to be realized within the first year following close.
For the trailing 12 months to September 30, 2024, the combined company posted revenue of around $220 million.
The combined company will continue to operate under the Quanterix name.
In pre-market trade on the Nasdaq, QTRX is up 9.80 percent at $12.88 and AKYA is up 45.11 percent at $3.860.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.